OGEN logo

Oragenics (OGEN) Company Overview

Profile

Full Name:

Oragenics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

February 25, 2004

Indexes:

Not included

Description:

Oragenics, Inc. (OGEN) is a biotechnology company focused on developing innovative treatments for infectious diseases and oral health. They work on new antibiotics and therapies to combat antibiotic resistance, aiming to improve patient care and public health through advanced research and development.

Events Calendar

Earnings

Next earnings date:

May 15, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 2, 2021
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jan 23, 2023

Analyst ratings

Recent major analysts updates

Jun 3, 21 Goldman Sachs
Neutral
Apr 16, 20 H.C. Wainwright
Neutral
Nov 15, 19 UBS
Neutral
Apr 26, 19 H.C. Wainwright
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025
OGEN
globenewswire.comFebruary 5, 2025

SARASOTA, Fla., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced that its Chief Medical Officer, James P. Kelly, MA, MD, FAAN, FANA, will be a featured panelist at the 12th Annual Brain Health Summit, held in conjunction with this year's Super Bowl celebrations in New Orleans on February 8, 2025. The event will focus on advancing awareness, prevention, and care for athletic concussions and exploring innovative approaches to traumatic brain injury (TBI) treatment.

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
OGEN
globenewswire.comOctober 18, 2024

SARASOTA, Fla., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, announced it will be presenting at the Centurion One Capital 2nd Annual Bahamas Summit to be held at the Rosewood Baha Mar Hotel on October 22-23, 2024, in Nassau, Bahamas. Michael Redmond, President of Oragenics, will participate in a corporate presentation and Q&A session on October 22, 2024 at 1:20 pm ET.

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
OGEN
globenewswire.comOctober 9, 2024

SARASOTA, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, today provided a corporate update reflecting on the company's progress throughout 2024, including key milestones in the development of ONP-002, its lead candidate for the treatment of concussions.

Oragenics, Inc. Announces Closing of Public Offering
Oragenics, Inc. Announces Closing of Public Offering
Oragenics, Inc. Announces Closing of Public Offering
OGEN
globenewswire.comSeptember 5, 2024

SARASOTA, Fla., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the closing of its previously announced offering of 3,078,378 shares of its common stock and pre-funded warrants to purchase up to 5,028,206 shares of common stock at an offering price of $0.55 per share and $0.549 per pre-funded warrant. Immediately after the closing of the offering, the Company has 8,659,071 shares of common stock outstanding and pre-funded warrants to acquire up to 5,028,206 shares of common stock outstanding. The exercise price of each pre-funded warrant is $0.001.

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients
Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients
Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients
OGEN
globenewswire.comAugust 21, 2024

• Falls and car accidents lead incidence of concussions in emergency departments • Spray-dried drug formulation allows for easy delivery to patients • No pharmaceutical treatment is available for concussion; drug, ONP-002, could be first of its kind to treat concussion SARASOTA, Fla., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the Company”), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the completion of its spray-dried formulation and filling in the nasal device for its lead candidate, ONP-002, for concussion.

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
OGEN
globenewswire.comAugust 16, 2024

SARASOTA, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("the Company"), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced recent and key 2024 business progress. The Company continues to execute its business strategy to develop and advance its lead candidate, ONP-002, for the treatment of concussion. Phase 2 human trials are being planned with anticipation of starting in the fourth quarter of this year.

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
OGEN
globenewswire.comAugust 14, 2024

• ONP-002 stability eliminates need for cumbersome cold storage • No FDA-approved pharmaceutical treatment available for concussion

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
OGEN
globenewswire.comAugust 12, 2024

– ONP-002 showed no cancer-causing DNA damage – Phase II clinical trial being planned SARASOTA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced its lead candidate for treating concussion, ONP-002, successfully completed a study that indicates it does not cause DNA damage and genotoxicity in an animal model.

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
OGEN
globenewswire.comAugust 8, 2024

The potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globally The potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globally

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
OGEN
globenewswire.comJune 27, 2024

SARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has completed a prototype of its automated intranasal device for use in concussed patients who are initially confused, dazed or unconscious in the acute phase of injury.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for Oragenics?
  • Does Oragenics pay dividends?
  • What sector is Oragenics in?
  • What industry is Oragenics in?
  • What country is Oragenics based in?
  • When did Oragenics go public?
  • Is Oragenics in the S&P 500?
  • Is Oragenics in the NASDAQ 100?
  • Is Oragenics in the Dow Jones?
  • When was Oragenics's last earnings report?
  • When does Oragenics report earnings?
  • Should I buy Oragenics stock now?

What is the ticker symbol for Oragenics?

The ticker symbol for Oragenics is NYSE American:OGEN

Does Oragenics pay dividends?

No, Oragenics does not pay dividends

What sector is Oragenics in?

Oragenics is in the Healthcare sector

What industry is Oragenics in?

Oragenics is in the Biotechnology industry

What country is Oragenics based in?

Oragenics is headquartered in United States

When did Oragenics go public?

Oragenics's initial public offering (IPO) was on February 25, 2004

Is Oragenics in the S&P 500?

No, Oragenics is not included in the S&P 500 index

Is Oragenics in the NASDAQ 100?

No, Oragenics is not included in the NASDAQ 100 index

Is Oragenics in the Dow Jones?

No, Oragenics is not included in the Dow Jones index

When was Oragenics's last earnings report?

Oragenics's most recent earnings report was on Nov 13, 2024

When does Oragenics report earnings?

The next expected earnings date for Oragenics is May 15, 2025

Should I buy Oragenics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions